TriangleNCT01919619 · OUTCOME
Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 30 days following the last dose of study drugs
What was measured
Any grade 4 hematological toxicity or grade 3-5 organ toxicity 30 days following the last dose of study drug.
Groups in this outcome
Autologous -Treatment (Lenalidomide and Ipilimumab)
Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
Allogeneic - Treatment (Lenalidomide and Ipilimumab)
Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
| Group | Source count |
|---|---|
| Autologous -Treatment (Lenalidomide and Ipilimumab) | 28 |
| Allogeneic - Treatment (Lenalidomide and Ipilimumab) | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Autologous -Treatment (Lenalidomide and Ipilimumab) | 10 | Not reported | Not reported | Not reported | Not reported |
| Allogeneic - Treatment (Lenalidomide and Ipilimumab) | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 28
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- Any grade 4 hematological toxicity or grade 3-5 organ toxicity 30 days following the last dose of study drug.
- groups
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- OG000
- title
- Autologous -Treatment (Lenalidomide and Ipilimumab)
- description
- Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Ipilimumab: Given IV Lenalidomide: Given PO
- id
- OG001
- title
- Allogeneic - Treatment (Lenalidomide and Ipilimumab)
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Up to 30 days following the last dose of study drugs
- title
- Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice